This site is intended for healthcare professionals
Managing Osteoarthritis-associated Pain
Declaration of sponsorship Pfizer and Lilly

Emerging therapies

Declaration of sponsorship Pfizer and Lilly
Read time: 20 mins
Last updated:10th Nov 2020
Published:10th Nov 2020
Current standard of care treatment for osteoarthritis (OA) pain does not provide satisfactory pain relief for many patients. Emerging therapies currently under clinical trial investigation target both the nociceptive and inflammatory pathways that promote OA pain.

Pharmacological strategies for managing pain in OA include paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular treatments and opioid analgesics for severe cases. These treatments are often inadequate, particularly in older patients that are less able to deal with adverse events or who possess contraindicated comorbidities. 

Adverse events include paracetamol-induced hepatotoxicity, gastrointestinal toxicities from NSAIDs and the risk of falls, delirium and dependency from opioids1. There is consequently a medical need for long-lasting, effective and tolerable treatments for OA pain.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: